분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-05-29 16:23:49 , Hit : 1655
 Pfizer Abandons AstraZeneca Takeover Bid



May 26, 2014  Agence France-Presse | IndustryWeek

.


What is in this article?:

Pfizer Abandons AstraZeneca Takeover Bid
'Culture of Innovation'



U.S. drugmaker Pfizer abandons its controversial bid to acquire British rival AstraZeneca after its final $117 billion offer was rejected last week.
..




(Photo by Christopher Furlong/Getty Images)




Advertisement


<script language="JavaScript" type="text/javascript"> document.write('<a href="http://adclick.g.doubleclick.net/aclk?sa=L&ai=B1_jFs9-GU-7AENCp9gX59oLQD7uByYQFAAAAEAEgm9CUHjgAWPPG35ujAWCbg-mEnCmyARR3d3cuaW5kdXN0cnl3ZWVrLmNvbboBCWdmcF9pbWFnZcgBCdoBU2h0dHA6Ly93d3cuaW5kdXN0cnl3ZWVrLmNvbS9nbG9iYWwtZWNvbm9teS9wZml6ZXItYWJhbmRvbnMtYXN0cmF6ZW5lY2EtdGFrZW92ZXItYmlkmAKQvwXAAgLgAgDqAhwvMzgzNC9pdy5ob21lL2dsb2JhbF9lY29ub215-AKB0h6QA-wJmAPgA6gDAeAEAaAGFg&num=0&sig=AOD64_0DT7-PAk8sJxBsgVxuQh42zfNimQ&client=ca-pub-0098407289527799&adurl=http://clk.atdmt.com/SLC/go/473454965/direct/01/" target="_blank"><img src="http://view.atdmt.com/SLC/view/473454965/direct/01/1150253062"/></a>'); </script> <noscript> <a href="http://adclick.g.doubleclick.net/aclk?sa=L&ai=B1_jFs9-GU-7AENCp9gX59oLQD7uByYQFAAAAEAEgm9CUHjgAWPPG35ujAWCbg-mEnCmyARR3d3cuaW5kdXN0cnl3ZWVrLmNvbboBCWdmcF9pbWFnZcgBCdoBU2h0dHA6Ly93d3cuaW5kdXN0cnl3ZWVrLmNvbS9nbG9iYWwtZWNvbm9teS9wZml6ZXItYWJhbmRvbnMtYXN0cmF6ZW5lY2EtdGFrZW92ZXItYmlkmAKQvwXAAgLgAgDqAhwvMzgzNC9pdy5ob21lL2dsb2JhbF9lY29ub215-AKB0h6QA-wJmAPgA6gDAeAEAaAGFg&num=0&sig=AOD64_0DT7-PAk8sJxBsgVxuQh42zfNimQ&client=ca-pub-0098407289527799&adurl=http://clk.atdmt.com/SLC/go/473454965/direct/01/" target="_blank"><img border="0" src="http://view.atdmt.com/SLC/view/473454965/direct/01/"></a> </noscript>  
.


NEW YORK – U.S. drugmaker Pfizer (IW 500/22) said on Monday it had abandoned its controversial bid to acquire British rival AstraZeneca (IW 1000/57) after its final $117 billion offer was rejected last week.

The announcement was the latest twist to a long-running saga that drew widespread attention over fears that British jobs and research capability would be lost and accusations that the tie-up was a cynical ploy by Pfizer to pay less tax.

Pfizer's takeover would have been the biggest deal of its kind in the pharmaceutical industry.

"Following the AstraZeneca board's rejection of the proposal, Pfizer announces that it does not intend to make an offer for AstraZeneca," the New York-based company said in a statement.

Pfizer had said that the combined company would deliver an expanded product pipeline, deep potential cost cuts and significant tax savings.

"We continue to believe that our final proposal was compelling and represented full value for AstraZeneca based on the information that was available to us," said Ian Read, chairman and CEO of Pfizer. "As we said from the start, the pursuit of this transaction was a potential enhancement to our existing strategy. We will continue our focus on the execution of our plans, bringing forth new treatments to meet patients' needs and remaining responsible stewards of our shareholders' capital."

Pfizer's proposal also included a controversial plan to re-domicile the combined company in Britain for tax purposes, in a move that would help it avoid paying billions of dollars in tax to the U.S. government.

AstraZeneca chairman Leif Johansson had attacked the U.S. pharmaceutical giant's pursuit of the firm, decrying it as "fundamentally driven by the corporate financial benefits to its shareholders of cost savings and tax minimisation."

'Culture of Innovation'



Responding to Pfizer's withdrawal on Monday, Johansson said AstraZeneca "would continue building on the momentum we have already demonstrated as an independent company."

"We have attractive growth prospects and a rapidly progressing pipeline," Johansson said. "AstraZeneca has a culture of innovation, with science at the heart of everything we do."

AstraZeneca chief executive Pascal Soriot had resisted the Pfizer overtures, bullishly advising shareholders that the company's revenues would almost double to $45 billion by 2023.

But analysts have expressed skepticism that Soriot's forecasts will prove accurate, speculating that AstraZeneca's sales by 2023 would remain in the range of $28 billion to $31 billion.

Pfizer's play for AstraZeneca comes as global pharmaceutical giants maneuver to cope with lost revenues from public-sector cutbacks in health care and patent expirations.

But Pfizer's withdrawal does not necessarily signal the end of the company's pursuit of AstraZeneca, although under British law the U.S. company must now wait six months before tabling another offer.

It could also make a higher bid in three months if AstraZeneca's board agrees to a fresh round of takeover talks.

Monday's developments did not immediately impact the U.S. and London stock markets, which were closed due to holidays. Pfizer's share price had slipped by 0.6% in Friday's trade to $29.49.

Copyright Agence France-Presse, 2014








887   존재하지 않았던 STAP 줄기세포  이성욱 2014/06/05 1664
886   금발은 어떻게 생겨날까? - DNA 글자 하나가 머리칼의 색깔을 바꾼다.  이성욱 2014/06/05 1649
885   광범위 목록화로 새로운 사람 단백질 193개 확인  이성욱 2014/06/02 1457
  Pfizer Abandons AstraZeneca Takeover Bid  이성욱 2014/05/29 1655
883   흉선의 종양억제 과정에 작용하는 다윈주의(자연선택) 메커니즘  이성욱 2014/05/27 2326
882   DNA의 규칙을 배반한 미생물  이성욱 2014/05/27 1591
881   [바이오토픽] 「미토콘드리아 대체」: 초읽기에 들어간 '부모가 셋인 아기' 탄생  이성욱 2014/05/26 2515
880   DNA가 비슷한 배우자를 선택하는 경향  이성욱 2014/05/23 1655
879   Novartis licenses Ophthotech eye drug in $1bn deal ('anti-PDGF APTAMER' as AMD drug)  이성욱 2014/05/21 1918
878   암 미세환경의 저산소증으로 인한 PD-L1 의 발현  이성욱 2014/05/20 2427
877   단순 포진 바이러스 탑재 줄기세포로 악성 뇌종양 치료를?  이성욱 2014/05/19 2102
876   항체 생성은 위험 신호일 때만  이성욱 2014/05/19 1615
875   암 백신과 항체 치료의 항암 효과  이성욱 2014/05/19 2134
874   Top 100 Most Prescribed, Top Selling Drugs  이성욱 2014/05/15 3074
873   마우스에서 뇌종양의 성장을 조절하는 단백질 발견  이성욱 2014/05/14 1957
872   외계의` DNA를 가진 최초의 생명체 탄생  이성욱 2014/05/14 1868
871   항-EGFR 항체 치료의 저항성을 극복하는 새로운 대장암 치료제  이성욱 2014/05/13 2357
870   Regeneron to Use Avalanche Platform in $640M+ Gene Therapy Collaboration  이성욱 2014/05/07 1621
869   인지과학의 수수께끼: 말(言)이 먼저일까, 생각이 먼저일까?  이성욱 2014/05/07 1643
868   DNA의 복사 기계가 일시 정지하는 경우, 암이 될 수 있어?  이성욱 2014/05/07 1769

[이전 10개] [1]..[11][12][13][14][15][16][17][18][19] 20 ..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN